Unfazed by PhII miss, Roche ushers Prothena's Parkinson's drug into late-stage trial — a $60M move
Prothena’s prasinezumab may not have met the primary endpoint in Phase II, but its partners at Roche are seeing enough to move it into …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
